UNIVERSITY OF MIAMI SCHOOL OF MEDICINE
Curriculum Vitae
Date: March 29, 2005
l. PERSONAL
Name: Judith Hurley, M.D.
Office Phone: 305-585-5196
Academic Rank: Associate Professor of Clinical Medicine
Primary Department: Department of Internal Medicine
Hematology/ Oncology Division
Secondary Appointment: None
Citizenship: USA
II.HIGHER EDUCATION
Institutional: 5/19/78 Yale University BA
6/19/84 Upstate Medical Center, Syracuse, NY MD
Non-Institutional:
Board Certification: National Board of Medical Examiners Part 1,2 & 3
1988 American Board of Internal Medicine
1991 American Board of Internal Medicine, Medical Oncology
2001 American Board of Internal Medicine, Medical Oncology
Licensure: 1991 Florida Medical License ME0058981
lll.EXPERIENCE
Academic:
7/84-6/85 Intern, OB/GYN, SUNY, Syracuse, NY
7/85-6/86 Intern, Internal Medicine, SUNY, Syracuse, NY
7/86-6/88 Resident, Internal Medicine, SUNY, Syracuse, NY
7/88-9/89 Fellow, Hematology/Oncology, SUNY, Syracuse, NY
10/89-6/90 Fellow, Hematology, New York University, NY
7/90-6/91 Fellow, Medical Oncology, Jackson Memorial Hospital,
Miami, FL
7/91-6/02 Assistant Professor of Clinical Medicine, University of
Miami Medical School
7/02-present Associate Professor of Clinical Medicine, University of
Miami Medical School
Hospital Appointments:
Jackson Memorial Hospital, Attending Physician,1991-present
University of Miami Hospital and Clinic, Attending Physician,1991-
present
VA Medical Center, Attending Physician, 1991-2002
Non-Academic: 1979 Lab Technician, Rockefeller University
7/1991-present Director, Hematology/Oncology Clinics, Jackson
Memorial Hospital, Miami
7/1998-present Consultant Medical Oncologist,
Taylor Breast Center,
Jackson Memorial Hospital,
Miami
Military: None
IV.PUBLICATIONS
JOURNAL ARTICLES:
Feun , Marini , Moffat , Savaraj , Hurley , and Mazumder . Cyclosporine A, alpha-interferon and
interleukin-2 following chemotherapy with BCNU, DTIC, cisplatin, and tamoxifen: A Phase II study
in advanced melanoma. Cancer Investigation 1:3-8, 2005
Hurley, Doliny, Reis, Silva, Gomez, De Zarraga, Welsh and Powell. Weekly Docetaxel and
Carboplatin as Primary Systemic Therapy for HER-2 negative Locally Advanced Breast Cancer.
Clinical Breast Cancer Vol 5 No 6(2005) pp 447-54
Lee, Doliny, Gomez-Fernandez, Powell, Reis and Hurley. Docetaxel and Cisplatin as Primary
Chemotherapy for the Treatment of Locally Advanced Breast Cancers. Clin Breast Cancer Vol 5
No 5(2004) pp 371-6.
Anderson, Mendoza, Payne, Valero, Palos, Nazario, Richman, Hurley, Gning, Lynch, Kalish and
Cleeland. Pain Education for Underserved Minority Cancer Patients: A Randomized Controlled
Trial. Journal of Clinical Oncology Vol 22 No 24 (2004) pp4918-25.
Hernandez-Reif, Ironson, Field, Hurley, Katz, Diego, Weiss, Fletcher, Schanberg, Kuhn and
Burman. Breast Cancer Patients have Improved Immune and Neuroendocrine Functions
following Massage Therapy. Journal of Psychosomatic Research 57 (2004) 45-52.
Anderson, Richman, Hurley, Palos, Valero, Mendoza , Gning and Cleeland. Cancer Pain
Management Among Minority Outpatients: Perceived Needs and Barriers to Optimal Control.
Cancer 2002; Vol 94, No 8: 2295-2304.
Feun, Savaraj, Hurley and Marini. Phase II Trial of Paclitaxel and Dacarbazine with Filgastim
Administration in Advanced Malignant Melanoma. Cancer Investigations 2002; Vol.20(3), 357-
361.
Hurley, Franco, Gomez-Fernandez, Reis, Velez, Doliny, Harrington, Wilkerson and Lee. Breast
Cancer and Human Immunodeficiency Virus: A Report of Twenty Cases. Clinical Breast Cancer
2001; Vol 2, No 3:215-22.
Guatam and Hurley. Phase II Study of Neoadjuvant Herceptin, Taxotere and Cisplatin in the
Treatment of Locally Advanced and Inflammatory Breast Cancer. Advances in Breast
Cancer;2001: Vol 3, No.3:5-7
Anderson, Mendoza, Valero, Richman, Russell, Hurley, DeLeon, Washington, Palos, Payne and
Cleeland. Minority Cancer Patients and their Providers: Pain Management Attitudes and
Practice. Cancer 2000;88:1929-38.
Feun, Savaraj, Hurley, Marini and Lai. A Clinical Trial of Intravenous Vinorelbine Tartrate plus
Tamoxifen in the Treatment of Patients with Advanced Malignant Melanoma. Cancer
2000;83:584-8.
Raez, Cabral,Cai, Landy, Sfakianakis, Byrne, Hurley, Scerpella, Jayweera and Harrington.
Treatment of AIDS-Associated Primary Central Nervous System Lymphoma with Zidovidine,
Ganciclovir and Interleukin 2. Aids Research and Human Retroviruses 1999;15:713-8.
Morrell, Lee, Hurley, Arias, Mies, Richman, Fernandez, Donofrio, Raub and Cassileth. Phase II
Trial of Neoadjuvant Methotrexate, Vinblastine, Doxorubicin and Cisplatinum (MVAC) in the
Treatment of Locally Advanced Breast Cancer (LABC). Cancer 1998;82:503-11
Kolber, Hurley, Moreno and Cabral. In Vitro Enhancement of T-Cell Receptor-Targerted Lysis
after IL-2 Treatment of PBL from HIV-Seropsitive Individuals. Clinical Immunology and
Immunopathology 1998; 86:226-34.
Feun, Savaraj, Soloman, Liebman and Hurley. Phase II Trial of Mitoxantrone, and Cisplatin in
Advanced Non-Small Cell Lung Cancer. American Journal of Clinical Oncology 1996;19:190-2.
Feun, Savaraj, Moffat, Robinson, Liebman, Hurley, Raub and Richman. Phase II Trial of
Recombinant Interferon- with BCNU, Cisplatin, DTIC and Tamoxifen in Advanced Malignant
Melanoma. Melanoma Research 1995;5:273-6.
ABSTRACTS:
Hurley, Doliny, Reis, DeZarraga, Gomez, Velez, Powell. Platinum Salts and Docetaxel as
primary therapy of locally advanced and inflammatory breast cancer:the final report of three
sequential studies. Breast Cancer Res Treat 2003; Vol 77
Hurley, Lunn, Turnquest, Reis, Doliny, Donenberg, De Zarraga, Mirhashemi. Breast Cancer in
the Bahamas:preliminary evidence for an increase in genetic risk. ASCO Proceedings. 2003.
Doliny, Velez, Jorda, Powell, Reis, Tang, Shonukan, Hurley. Weekly Carboplatin and Docetaxel
as neoadjuvant therapy in locally advanced and inflammatory breast cancer. ASCO Proceedings,
2003.
De Zarraga, Doliny, Reis, Powell, Velez, Gomez, Tang, Hurley. Cardiotoxicity of neoadjuvant
Herceptin, Docetaxel and Cisplatin is related to BMI. ASCO Proceedings, 2003.
Morrell, Lee, Reis, Hurley. MVAC as neoadjuvant therapy in locally advanced and inflammatory
breast cancer: A ten year update. ASCO Proceedings, 2003.
Wang H, Hurley J, Jorda M, Gomez-Fernandez C. Gene Amplification and Protein
Overexpression of HER2 in Gastric Adenocarcinoma. Modern Pathology 2003; (16):612A.
Hurley, Doliny, Silva, Powell, Shayker, Velez, Reis and Lee. Is there an alternative to
anthracycline based chemotherapy: an evaluation of a non-anthracycline containing regimen as
neoadjuvant therapy in locally advanced and inflammatory breast cancer. Breast Can Res Treat
2002;Vol 76, Supplement 1, No #155.
Hurley, Doliny, Silva, Gomez-Fernandez, Reis, Velez, Castillo, Bateman, Franco, Guatam.
Neoadjuvant Herceptin/Taxotere/Cisplatin in the Treatment of Locally Advanced and
Inflammatory Breast Cancer. ASCO Proceedings, No.196 , 2002.
Franco, Silva, Bateman, Doliny, Jorda, Castillo, Reis, Velez and Hurley. Neoadjuvant treatment
of locally advanced and inflammatory breast cancer with weekly taxotere and carboplatin in
tumors that do not overexpress her-2. ASCO Proceedings, No 2048, 2002.
Hurley, Doliny, Velez, Guatam, Reis, Silva, Gomez-Fernandez, Lee and Franco. High Rate of
Axillary Node Clearance with Neoadjuvant Herceptin, Taxotere and Cisplatin in Locally Advanced
and Inflammatory Breast Cancer. Breast Cancer Research and Treatment 2001;Vol 69, No 3
#516
Hurley, Franco, Velez, Doliny, Gomez-Fernandez, Powell and Lee. Primary Therapy with
Herceptin, Taxotere and Cisplatin in Locally Advanced and Inflammatory Breast Cancer. ASCO
Proceedings, No.1871, 2001.
Feun, Mazumder, Marini, Elgart, Hurley and Savaraj. A Pilot Study of the Initiation of
Autoimmune Reaction to Tumor in Melanoma Patients by Cyclosporine A, Alpha Interferon and
Interleukin-2 following Chemotherapy with BCNU, DTIC, Cisplatin and Tamoxifen. ASCO
Proceedings, No., 2001.
Harrington, Hurley, Cabral, Cohen, Hamilton, Byrne and Byrnes. Phase II Trial of Chemotherapy
with and without Antiretroviral Therapy in the Treatment of AIDS Associated Large Cell
Lymphoma. ASCO Proceedings, No.75, 2000.
Hurley, Doliny, Gomez,Raez, Boggs, Franco and Lee. High Complete Response Rate of Locally
Advanced Breast Cancer (LABC) to Neoadjuvant Docetaxel and Cisplatin Chemotherapy. ASCO
Proceedings, No 494, 2000
Feun, Savaraj, Hurley and Marini. Phase II Trial of Taxol and DTIC with Filgrastim
Administration in advanced Malignant Melanoma-Final Report. ASCO Proceedings, No. 2252,
2000.
Hurley J, Lee Y, Boggs J and Franco S. Breast Cancer and Human Immunodeficiency Virus: A
Report of Sixteen Cases. Breast Cancer Research and Treatment 1999,Vol 67, No. # 139.
Doliny, Hurley, Raez, Boggs, Mies, Cassileth and Lee. Phase II Trial of Neoadjuvant Docetaxel
and Cisplatinum for the Treatment of Locally Advanced Breast Cancer. ASCO Proceedings, No.
319, 1999
Lee, Hurley, Antunez, Cohen, Arias et al The Use of Vinorelbine and G-CSF in the Treatment of
Poor Prognosis Acute Myeloid Leukemia. ASCO Proceedings No. 116, 1999
Hurley, Restrepo,Boggs, Lee et al The Use of Neoadjuvant Doxil in the Treatment of Stage III
Breast Cancer. ASCO Proceedings, No.359, 1999
Lee, Manocha, Hurley, Lema and Cassileth, Use of Vinblastine in the Treatment of Poor
th
Prognosis Acute Myelocytic Leukemias, 8 International Congress on Anticancer Treatment,
Paris, February 3, 1998
Raez, Hurley, Jayweera, Scerpella, Landy, Cai, Sfakanakis, Cabral and Harrington. Treatment of
Aids related Primary Central Nervous System Lymphomas with Azothymidine, Gancylovir and
Interleukin 2. Blood, 1997;90: 342.
Morrell, Lee, Hurley, Arias, Richman and Cassileth, Phase II Trial of Neoadjuvant Methotrexate,
Vinblatine, Doxorubicin and Cisplatin in the Treatment of Locally Advanced Breast Cancer,
Proceedings of the American Society of Clinical Oncology, Vol. 16, 1997,pp
V.PROFESSIONAL- FUNDED RESEARCH
National Cancer Institute
Pain Symptoms of Cancer: Assessment and Treatment
2-R01 CA06582
PI: Charles Cleeland,M.D. (MD Anderson)
(Role on Project: Collaborator 15%) 2/1/2005-
Total direct costs: $216,075 Indirect costs:
National Institute of Health
Southeastern AIDS Oncology Consortium (AIDS Malignancy Consortium Clinical Trials Grant)
1-UO1 CA 700580-03
PI: William Harrington, M.D.(University of Miami)
(Role on Project: Consultant, 15%) 8/1/99-7/31/04
Total direct costs: $227,393/year Indirect costs:
National Cancer Institute
Cancer Pain Relief Skills for Minority Outpatients
1-U01 CA-93-45
PI Charles Cleeland, M.D. (M.D. Anderson)
(Role on Project: Collaborator, 10%) 3/1/97-5/31/99
Total direct costs: $90,641 Indirect costs: $48,040
Avon Research and Care Network
Program for the Medically Underserved Breast Cancer Patient
PI: Judith Hurley, M.D. 6/1/02-6/1/04
Total direct costs: $450,000 Indirect costs: $50,000
Aventis Pharmaceuticals, Inc.
Phase II Trial of Dose Dense Herceptin, Taxotere and Carboplatin in the Treatment of Breast
Cancer.
PI: Judith Hurley, M.D. 6/1/05-6/1/06
Total direct costs: $147,750 Indirect costs: $48,250
Aventis Pharmaceuticals, Inc.
Phase II Trial of Weekly Taxotere and Carboplatin in the Treatment of Locally Advanced and
Inflammatory Breast Cancer.
PI: Judith Hurley, M.D. 3/1/01-3/1/03
Total direct costs: $147,750 Indirect costs: $48,250
Aventis Pharmaceuticals, Inc.
Phase II Trial of Neoadjuvant Docetaxel and Cisplatinum in the Treatment of Locally Advanced
Breast Cancer
PI: Judith Hurley, M.D. 3/1/98-9/1/99
Total direct costs: $75,000 Indirect costs: $25,000
Aventis Pharmaceuticals,Inc. and Amgen, Inc.
Phase II Trial of Neoadjuvant Herceptin, Taxotere and Cisplatin in the Treatment of Locally
Advanced and Inflammatory Breast Cancer
PI: Judith Hurley, M.D. 2/1/00-2/1/03
Total direct costs: $228,750 Indirect costs: $76,250
Glaxo-Wellcome Pharmaceuticals, Inc.
The Use of Vinorelbine in the Treatment of Poor Prognosis Acute Myeloid Leukemia.
PI: Judith Hurley, M.D. 4/1/98-10/1/00
Total direct costs: $30,000 Indirect costs: $10,000
SEQUUS Pharmaceuticals, Inc.
960 Hamilton Court
Menlo Park, CA. 94025
The Feasibility of Breast Conservation after Neoadjuvant Doxil in Stage III Breast Cancer
PI Judith Hurley, M.D. 3/1/96-8/1/97
Total direct costs: $22,500 Indirect costs: $7,500
Novartis Pharmaceutical Corporation
556 Morris Ave
Summit, NJ 07901
A Double Blind Randomized Parallel Group Phase III Trial Comparing the Efficacy of 4 Months of
Preoperative Letrozole with Preoperative Tamoxifen
PI Helen Smith (Novartis)
Role on Project: Collaborator 2/1/98-9/1/99
Total direct costs: $26,500 Indirect costs: $8,750
Professional Organizations:
American Society of Clinical Oncology, Member 1998-present
Invited Speaker
Taxotere Advisory Board, Women in Oncology, August 25, 2001
Taxotere Advisory Board, Women in Oncology, March 16, 2002
Breast Cancer International Research Group, June 22, 2002
Didactic Teaching Conference, Hematology/Oncology, University of Miami, October 23, 2002
Honors and Awards:
Glen Leak Memorial Fellowship in Cancer Research, SUNY, Syracuse, NY 1980
Dr. Sarah E. Howell Award from the Women’s Cancer League January 20, 2004
Vl.TEACHING
Awards Received
Yearly Teaching Award - Hematology/Oncology Division
1995, 1996, 1997,1998, 1999, 2002
Teaching Specialization
Mechanisms of Disease Course-Instructor 1991-4
Grand Rounds
Internal Medicine Department
Breast Cancer for Internists 4/00
Family Practice Department
A Practical Approach to Breast Cancer 9/98, 4/01
Sylvester Cancer Center
Cancer in Pregnancy 10/94
Locally Advanced Breast Cancer 5/00
Resident’s Rounds- Oncologic Emergencies 8/00, 8/02, 8/03, 8/04
Teaching Attending, Division of Hematology/Oncology, 1991-present
Ward Attending on WW12
Director and Attending JMH Oncology Clinic
Consultant- Breast Health Center, Jackson Memorial Hospital
VII. SERVICE
2000-present Pharmacy and Therapeutics Committee- Chemotherapy Committee, Jackson
Memorial Hospital
2000-2002 American Cancer Society, Florida Division, Colorectal Cancer Subcommittee,
Member.
1995-97 Educational Task Force, Jackson Memorial Hospital, Chairman.
1995-97 Ambulatory Quality Improvement Council, Jackson Memorial Hospital, Member .